الفهرس 
Introduction & aim of the workOnly 14 pages are availabe for public view
 |  | from | 232 |  |  |
| | | from | 232 | | |
Abstract
Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third cause of cancer-related mortality worldwide. HCC is an end result of some chronic infections with the hepatitis B (HBV) or the hepatitis C (HCV).The population at risk is composed of chronic liver patients at the stage of extensive fibrosis or cirrhosis
The expression of GP73 undergoes a notable increase in chronic liver diseases, particularly in HCC cells A number of studies have described the use of GP73 as a serum marker for HCC; however, the results have been inconsistent and shown evident heterogeneity
Treatment options of HCC are numerous, local interventional therapy in the form of RFA or TACE provided a chance for patients who could not fulfill criteria for surgical resection or liver transplantation
Investigation of the role of serum markers not only in diagnosis but also as prognostic factors in prediction of treatment outcomes after different modalities of treatment will improve survival.